Bevacizumab在青光眼治疗中的研究进展  

Advances of Bevacizumab in treatment of glaucoma

作　　者：张发梁[1] 刘金华[2] 

机构地区：[1]广西北海市人民医院眼科,536000 [2]广西医科大学第一附属医院眼科

出　　处：《临床眼科杂志》2010年第5期472-474,共3页Journal of Clinical Ophthalmology

摘　　要：Bevacizumab是一种合成的抗血管内皮生长因子抗体片段,通过前房或玻璃体腔注射Bevacizumab,能促进虹膜和前房角新生血管的消退,显著降低眼压,可单独或联合手术治疗新生血管性青光眼;同时在青光眼滤过性手术中或在失败的滤过泡中应用,能显著提高手术的成功率,为青光眼的治疗开辟了新的途径,本文综述了这方面的进展。Bevacizumab is a recombinant antibody fragment angis vascular endothelial growth factor.Anteior chamber or intravitreal injection of bevacizumab highlight regression of neovascularization of both the iris and angle,Introcular pressure decreased.Used bevacizumab as wound modulator to retard fibroblast proliferation in trabeculectomy and to rescue a faliling filtering bleb,filtering surgery became safe and efficacy.It is likely to extend our therapeutic options in the management of glaucoma.This article reviews current clinical studies documenting the use of Bevacizumab in glaucoma.

关 键 词：BEVACIZUMAB 血管内皮生长因子 新生血管性青光眼 小梁切除术 虹膜新生血管 

分 类 号：R779.6[医药卫生—眼科]